PCVX
Vaxcyte Inc
NASDAQ: PCVX · HEALTHCARE · BIOTECHNOLOGY
$57.32
-2.40% today
Updated 2026-04-29
Market cap
$8.28B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-5.63
Dividend yield
—
52W range
$28 – $65
Volume
1.3M
Vaxcyte Inc (PCVX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | $1.04M | $1.23M | $1.41M | $1.80M | $9.20M | $75.00M | $15.85M | — |
| Gross profit | — | $-1.04M | $-1.23M | $-1.41M | $-1.80M | $-9.20M | $-75.00M | $-15.85M | — |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $12.79M | $30.14M | $45.61M | $73.56M | $78.41M | $169.45M | $332.34M | $476.64M | $794.31M |
| SG&A | $5.05M | $5.39M | $8.55M | $16.02M | $25.26M | $39.81M | $60.70M | $92.90M | $129.37M |
| Operating income | $-17.83M | $-35.53M | $-54.15M | $-89.58M | $-103.67M | $-232.26M | $-468.04M | $-569.55M | $-923.67M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $-17.21M | $-28.37M | $-49.00M | $-87.81M | $-96.61M | $-214.03M | $-392.10M | $-448.08M | $-741.77M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-17.83M | $-29.41M | $-50.23M | $-89.21M | $-100.07M | $-223.48M | $-402.27M | $-463.93M | $-766.63M |
| Interest expense | $0.00 | $75000.00 | $40000.00 | $7000.00 | $7000.00 | $2000.00 | $0.00 | $0.00 | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.24M | $-29.48M | $-50.27M | $-89.22M | $-100.08M | $-223.49M | $-402.27M | $-463.93M | $-766.63M |
| Net income growth (YoY) | — | -71.0% | -70.5% | -77.5% | -12.2% | -123.3% | -80.0% | -15.3% | -65.2% |
| Profit margin | — | — | — | — | — | — | — | — | — |